Cardiovascular Cell Therapy Research Network

Cardiovascular Cell Therapy Research Network
Name	Cardiovascular Cell Therapy Research Network
Formation	2006
Type	Research network
Headquarters	United States
Parent organization	National Heart, Lung, and Blood Institute

Contents

Cardiovascular Cell Therapy Research Network The Cardiovascular Cell Therapy Research Network was a multicenter clinical research consortium established to evaluate cell-based therapies for myocardial infarction, heart failure, and related cardiovascular disease conditions. It was funded and coordinated within the framework of the National Institutes of Health, with operational ties to the National Heart, Lung, and Blood Institute, and conducted trials across academic centers associated with institutions such as Duke University, University of Texas Southwestern Medical Center, Vanderbilt University Medical Center, Cedars-Sinai Medical Center, and Mayo Clinic. The Network interfaced with regulatory bodies including the Food and Drug Administration and collaborated with professional societies like the American College of Cardiology and the American Heart Association.

History

The Network was launched in the mid-2000s against the backdrop of early translational work by investigators at Harvard Medical School, Stanford University School of Medicine, Johns Hopkins School of Medicine, University of Pennsylvania School of Medicine, and Massachusetts General Hospital who reported preclinical and pilot clinical results for cell therapy in ischemic heart disease. Its creation followed initiatives by the National Institutes of Health and program planning panels convened with representatives from Duke University Medical Center, University of Minnesota, Yale School of Medicine, Columbia University Irving Medical Center, and University of California, Los Angeles. Early Network protocols built on prior studies such as those conducted at Cleveland Clinic, Brigham and Women's Hospital, Mount Sinai Hospital (Manhattan), University College London, and Imperial College London that explored autologous and allogeneic cell sources.

The Network designed randomized, multi-center protocols testing cell types including bone marrow-derived mononuclear cells studied in trials akin to early work from University of Louisville School of Medicine and Beth Israel Deaconess Medical Center, mesenchymal stromal cells reflecting investigations at University of Miami Miller School of Medicine and University of Minnesota, and cardiac progenitor cells following research from Baylor College of Medicine and University of Southern California Keck School of Medicine. Major trials enrolled participants at sites such as Duke University Hospital, Vanderbilt University Medical Center, Cedars-Sinai Medical Center, Mayo Clinic Hospital, and Yale-New Haven Hospital. Trial design and endpoints referenced methods from CONSORT, collaboration with statistical groups at Johns Hopkins Bloomberg School of Public Health, and imaging adjudication tied to centers like University of Pennsylvania Perelman School of Medicine and Brigham and Women's Hospital.

Network publications contributed to the evidence base on safety, feasibility, and efficacy signals for cell therapy in post-infarction remodeling and chronic heart failure, complementing reports from Cleveland Clinic, Massachusetts General Hospital, St. Bartholomew's Hospital, Royal Brompton Hospital, and Guy's and St Thomas' NHS Foundation Trust. Findings informed guideline deliberations among organizations such as the European Society of Cardiology, American College of Cardiology, American Heart Association, Heart Failure Society of America, and regulatory guidance from the Food and Drug Administration. The Network's datasets were cited in meta-analyses and systematic reviews authored by consortia including Cochrane Collaboration, academic groups at University of Cambridge, University of Oxford, and policy reports from the Institute of Medicine. Its legacy influenced subsequent cell- and gene-therapy trials at centers like Stanford University, Harvard Medical School, University College London, and biotechnology partnerships emerging from Biogen, Amgen, Athersys, and Mesoblast.

Funding primarily originated from the National Heart, Lung, and Blood Institute within the National Institutes of Health, supplemented by cooperative agreements with academic institutions such as Duke University, Vanderbilt University, Cedars-Sinai Medical Center, and philanthropic contributions from entities connected to American Heart Association chapters and foundations. Scientific collaborations extended to international partners at University College London, Imperial College London, Charité – Universitätsmedizin Berlin, and Karolinska Institutet, and aligned with translational infrastructure at Translational Research Institute, Clinical and Translational Science Award hubs, and industry partners including Pfizer, Novartis, and Johnson & Johnson for ancillary studies and manufacturing support.

The Network operated under ethical frameworks enforced by institutional review boards at Yale University, University of Pittsburgh, University of Michigan, Emory University, and Northwestern University, adhering to regulations from the Food and Drug Administration and policy guidance influenced by panels convened at National Academy of Medicine and World Health Organization. Safety monitoring involved data and safety monitoring boards with experts from Johns Hopkins University, Mayo Clinic, Cleveland Clinic, Brigham and Women's Hospital, and Stanford University, addressing risks such as immunogenicity, arrhythmogenesis, and tumorigenicity noted in preclinical reports from University of Pennsylvania, Harvard Medical School, and Massachusetts Institute of Technology. Ethical debates engaged bioethicists from Columbia University, University of Chicago, Georgetown University, and patient advocacy groups including American Heart Association, balancing innovation, informed consent, and trial access.

Category:Cardiology research networks